30-Second Overview: Chi-Huey Wong is one of the most important scientists in the global glycoscience field. In 2014, he received the Wolf Prize in Chemistry, known as the "Nobel Precursor"—historically, 70% of its recipients have ultimately won the Nobel Prize. The Nobel Committee once prepared to come to Taiwan to meet with him. However, the 2016 OBI Pharma case forced him to resign as president of Academia Sinica at his closest moment to the Nobel Prize. He said of himself: "I promoted the Biotech Development Act, and I became the first victim of it." In 2019, he was acquitted in the first trial, but he said "Justice has arrived, but reputation cannot be restored."
In January 2014, Chi-Huey Wong, a chemistry professor at Scripps Research Institute, received the Wolf Prize in Chemistry. This prize is known as the "Nobel Precursor"—historically, 70% of its recipients ultimately won the Nobel Prize. Those in Taiwan's academic circles understood: this was the closest a Taiwan-born scientist had come to the Nobel Prize in Chemistry.
Two years later, members of the Nobel Committee in Chemistry were originally planning to come to Taiwan to meet with him. Then the OBI Pharma case erupted. Wong himself said: "I asked them not to come, because that situation was not appropriate."
From Tainan to MIT: A Chemist's Foundation
Born in 1948 in Tainan, Chi-Huey Wong graduated from National Taiwan University's Department of Chemistry and then went to the United States. In 1982, he earned his Ph.D. in organic chemistry from the Massachusetts Institute of Technology (MIT). At that time, Taiwanese students who could conduct doctoral-level research at MIT were rare, so his starting point was already remarkable.
After his postdoctoral fellowship, Wong served as an assistant professor at Texas A&M University, then moved to the California Institute of Technology (Caltech), becoming a professor of chemistry there in 1989. Eventually, he settled at Scripps Research Institute, where he established his own laboratory and began systematically addressing the core challenges of glycoscience.
Glycoscience (carbohydrate chemistry) had long been a niche field in chemistry—not because carbohydrates were unimportant, but for the opposite reason. Carbohydrate molecules cover the surface of every cell, controlling immune recognition, viral infection, and cancer metastasis. Rather, it was because the structures of carbohydrate molecules are extremely complex; synthesizing a specific carbohydrate molecule could take a laboratory months of work, which was discouraging.
Wong spent nearly two decades solving this efficiency problem.
Programmable One-Pot Synthesis: Glycoscience Enters the Fast Lane
Wong's most critical technological breakthrough was "programmable one-pot synthesis."
Traditional carbohydrate molecule synthesis required numerous steps: each time a glycosyl unit was added, other positions had to be protected, the reaction run, the mixture purified, then protected again, reacted again... dozens of steps were routine. Wong's method was to "program" the entire synthesis procedure—predesigning the sequence and conditions of each reaction so that all steps could be automatically completed sequentially in a single container, like inputting a complex recipe into a fully automated cooking machine that outputs the molecule you want.
This method was not merely elegant chemistry; it was a key that unlocked the door to drug development.
With synthesis speeds improved, researchers could now systematically test how different carbohydrate molecules affected cancer cells, viruses, and bacteria. Wong's laboratory thus became one of the fastest places globally for glycoscience research.
📝 Scripps described his research in its award citation this way: "Wong's discoveries and technologies have fundamentally shaped our understanding of complex carbohydrates and glycoproteins, as well as uncovered new therapeutic strategies to treat major diseases." The landscape of glycoscience changed because of him.
Glycoprotein Vaccines: A New Path Against Cancer
Wong's most closely watched applied research was the development of cancer vaccines using glycochemistry technology.
Cancer cells have specific glycoprotein markers on their surface (carbohydrate antigens) that differ from normal cells. If these glycoprotein antigens could be synthesized and the immune system taught to recognize them, in theory the human body could be trained to actively attack cancer cells, achieving a vaccine effect.
His laboratory successfully synthesized multiple glycoprotein antigens related to breast cancer and prostate cancer, and demonstrated in animal experiments that these synthetic molecules could trigger effective immune responses. This technological approach differed from the currently popular mRNA vaccines; it was a more classical direction in molecular immunology, but its potential was still highly valued by the international cancer research community.
By 2016 before the OBI Pharma case erupted, Wong had published more than 600 papers with over 40,000 citations, making him one of the most highly cited researchers in the global glycoscience field.
The Wolf Prize: Coming Closest to the Nobel
The 2014 Wolf Prize in Chemistry citation read: "In recognition of his pioneering contributions to glycochemistry and glycobiology, and breakthrough research in developing glycoprotein vaccines for cancer treatment."
The Wolf Prize, awarded by Israel's Wolf Foundation, ranks second only to the Nobel Prize in the scientific world and is regarded as the "Nobel Precursor." Historically, 70% of Wolf Prize in Science recipients have later won the Nobel Prize.
In 2015, Wong received the Shaw Prize for Life Science and Medicine, further consolidating his position in the international academic world.
Those two years were the convergence point of the peak of his career: the most important prizes, the highest academic prestige, and a group of Nobel Committee members waiting for the right moment.
Returning to Taiwan: A Decade of Reform as Academia Sinica President
In 2006, Wong accepted an invitation from President Chen Shui-bian to return to Taiwan and serve as president of Academia Sinica.
At that time, he was already a member of the National Academy of Sciences and the American Academy of Arts and Sciences, with a secure position at Scripps. Returning to Taiwan came at a cost: he had to relinquish his research leadership, transitioning from scientist to administrative leader, and had to face various constraints within Taiwan's academic system.
But he chose to return because Taiwan's scientific research needed someone with international vision to advance it.
During his decade as president (2006–2016), he primarily pursued two initiatives:
First, elevating Academia Sinica's international research standards. During his tenure, Academia Sinica's ranking in SCI paper citations rose from sixth in Asia to third. He actively recruited overseas scholars, established more flexible hiring mechanisms, and enabled Academia Sinica's salaries and conditions to compete internationally.
Second, promoting industry-academia collaboration and technology transfer. He participated in promoting revisions to the Biotech and Pharmaceuticals Industry Development Act, establishing a framework through which scholars, institutions, and enterprises could legally share the benefits of technology transfer. His thinking was: Taiwan's academic research cannot be limited to writing papers; it must translate into industry to produce genuine value for society.
OBI Pharma was a concrete case under this industry-academia collaboration logic.
The OBI Pharma Case: A Controversy That Made Nobel Committee Members Hesitate
In February 2016, OBI Pharma's new breast cancer drug OBI-822 failed to meet the preset efficacy standards in the unblinding trial. When the news broke, the stock price was cut in half that day.
A few weeks later, media outlets revealed: Wong's daughter held a large number of OBI Pharma shares that had been acquired at low prices before the trial unblinding. The question arose: Wong was president of Academia Sinica, Academia Sinica had licensed its carbohydrate chemistry technology to OBI Pharma; his daughter held a large share of OBI Pharma; was there a conflict of interest here?
In March 2016, Wong announced his resignation as president of Academia Sinica.
Prosecutors indicted him on charges of corruption, alleging he used his position as president to secure research resources for OBI Pharma and allowed his daughter to profit from this. The Control Yuan passed an impeachment case, determining that he "abused authority to benefit himself and others, seriously damaging the government's reputation."
Wong said at a press conference: "This unfortunate result stemmed from a misunderstanding of the technology transfer and industry-academia collaboration system. I promoted the Biotech Development Act, and I became the first victim of it."
During the case, members of the Nobel Committee in Chemistry had originally planned to come to Taiwan to visit him. Wong later said he knew of their plan and proactively asked them to cancel because he was under investigation—"that situation was not appropriate."
📝 This was not just one person's experience, but a public test of Taiwan's academic community regarding industry-academia collaboration. A policy designer who promoted technology transfer faced criminal charges as a result of that policy's implementation, which resulted in everyone becoming more hesitant to engage in technology transfer.
2019: Acquittal Verdict, but Reputation Cannot Be Restored
In 2019, the Shilin District Court acquitted Wong of all charges.
The court determined that Wong's actions did not meet the elements of the crime of corruption—his daughter's acquisition of OBI Pharma stock was through normal technology transfer mechanisms, with no subjective intent to profit illegally.
On the day the verdict was announced, Wong issued a statement; his first words were: "Justice has arrived, but reputation cannot be restored; I hope to close this chapter here."
These words expressed a cruel truth of the modern legal system: an acquittal verdict can keep you out of prison, but it cannot restore what you have lost—the reputation of a decade as president of Academia Sinica, and the opportunity that never came when the Nobel Committee did not visit Taiwan.
In 2021, when the Control Yuan had new members elected, Wong filed a petition requesting a reinvestigation of the impeachment case, mentioning the Nobel Prize in his petition. Those close to him said he had never let go of the matter.
The Continuing Impact of Glycoscience
Wong's research achievements did not disappear because of the controversy.
The glycoscience platform he established at Scripps remains one of the most important centers in the world for glycoscience research. The synthesis techniques he developed are widely used in new drug development, cancer vaccine research, and diagnostic reagent preparation. The doctoral students and postdoctoral researchers he mentored are now scattered across top institutions including Harvard, Stanford, and MIT, continuing to advance the frontier of glycoscience.
The 2015 Shaw Prize for Life Science and Medicine and the 2022 Tetrahedron Prize for Innovation in Organic Synthesis were both awarded after the OBI Pharma case and are among the highest honors in chemistry. His research career did not end because of the controversy.
Wong once said: "I never thought about prizes... those are things external to oneself. When people recognize you, you're happy, but if you're always chasing prizes, research actually suffers."
The Nobel Prize never came. But glycoscience, because of him, changed the entire boundary of possibilities in drug development. That contribution does not need a prize to confirm it; it continues reacting in countless laboratory test tubes around the world.
References
- Chi-Huey Wong - Wikipedia (English) (primary source compilation)
- 2014 Wolf Prize in Chemistry - Scripps Research (primary)
- The Taiwanese Closest to the Nobel Prize Right Now - Harvard Business Review Taiwan (2025 in-depth report)
- Chi-Huey Wong Reveals: Nobel Committee's Taiwan Visit Was Cancelled - United Daily News
- Control Yuan Impeachment Announcement (primary)
- 2022 Tetrahedron Prize - Scripps Research (primary)